ADAGENE INC-ADR
Develops proprietary therapeutic antibodies and bispecific biologics.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Adagene stock with a target price of $5.5, indicating good growth potential.
Financial Health
Adagene is struggling to generate significant revenue and has limited financial resources.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ADAG
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones Matter
Clinical trial readouts, INDs and partnership deals can drive revaluation, though outcomes are uncertain and timing may be unpredictable.
Collaborations and Partners
Licensing and alliances can de‑risk programmes and provide funding, but agreements vary and may affect long‑term upside.
Small‑Cap Volatility
With a sub‑$100M market cap, shares can swing sharply on news; this may suit risk‑tolerant investors but carries higher downside.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
